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INTRODUCTION
Chemotherapy-related toxicities limit its maximal us e. A main limitation is their non-discriminatory action towards normal organs in patients. Delivering drugs t o breast cancer cells specifically is a considera ble challenge. Previous strategies to ide ntify markers specific for breast cancer cells oft en faced difficulties due to heterogeneity of cancer cells and similarities between cancer and non-cancer brea st cells. We aim to develop a new approach to treat breast cancer by targeting the commonalities that exist in all breast tissue (normal and malignant) to enhance delivery of chemotherapy to breast cancer and minimize delivery to non-breast tissu e. Our drug d elivery platf orm is based on the adeno-associa ted virus (AAV), a 25 n m virus that is currently in clinical trials for a variet y of gene th erapy applications. We propose to create novel chemotherapeutic-carrying virus nanoparticles (VNPs) for localized drug delivery to breast tissue.
BODY Task #1: Chemical conjugation of paclitaxel to virus scaffold
Paclitaxel was reacted with succinic anhydride to obtain taxol-2'-succin ate. We attempted to use other one-step methods to synthesize taxol-NHS ester, but had difficulty getting rid of the DMSO from the product. So we used a two-step synthesis, a nd intermediate SDPP (N-hydro xy-succinimido diphenyl phosphate) wa s synthesized to increase the yield in step 3. Taxol-2'-succ inate was reacted with SDPP to form ta xol-NHS ester (Fig. 1) .
The taxol-NHS ester was purified by column chromatography using hexane and eth yl acetate as solvents. T he purity of the product was confirmed by thin la yer chromatography. The Rf value is 0.52 in ethyl acetate. Th e mass was confirmed with MALDI-MS (Fig. 2) .
The taxol-NHS ester was reacted with AAV capsids at variou s molar ratios of taxol-NHS ester to lysine resid ues. There exist 1,08 0 lysine resid ues on the virus capsid. The reactio n was done overnight at 4 o C, with less than 10% DMSO in the final solution (Fig. 3) . The reaction mixture was dial yzed against DPBS buffer to get rid of un-reacted taxol-NHS ester. Control exp eriments indicated that t he AAV capsid is stable in 10% DMSO o vernight. The TEM image in Figure 3 sho ws a virus capsid that was incub ated in 10% DMSO overni ght. No visible alteratio ns to the virus ca psid can be observed. Reaction was also tested with 4 h ours reactio n time inste ad of overnight, however no virus band s appeared in We stern blots. Ther efore, we d ecided to carry out the conjugat ion reactions overnight at 4 o C. To determine if taxol was successfully conjugated onto the AAV capsid, we ran two Western blots -one against the virus capsid sub units and the other against taxol. In t he anti-capsid subunit blot (Fig. 4A) , a slight increase in the sizes of VP1, VP2, and VP3 can be observed. When the blot was probed with an antitaxol antibody, dramatic shifts in the sizes of all 3 subunits can be seen (Fig. 4B) . At this point, it is unclear why the shifts o bserved in the 2 blots are not e quivalent. One potential hypothesis is that there exists a heterogeneous mixture of subun its conjugated to varying degrees an d the ones conjugated with detecta ble levels of taxol cannot be detected with the B1 antibody, perhaps due to masking of the B1 epitope. For Western blo tting, samples were de natured and run on 7% Tris-Acetat e gels. Pro tein was tra nsferred to a nitrocellulose membran e and blocked with 5% skim milk for 1 h. Membranes were probed with prim ary antibody (1:200 dilution for B1 antibody, 1:100 dilution for anti-taxol antibody) for 1 h, rinsed, and probed with a horseradish peroxidase conjugated secondary antibody for 1 h. Images were taken using a FlourChem FC2 imager. TEM imaging of virus capsids conjugated with taxol suggest that the capsids are intact (Fig. 5) . Conjugation of taxol onto the virus capsid appears to pre vent detection by the A20 a ntibody that detects intact capsids. In Figure 6A , a high titer of viral genomes/ml can be detected with QPCR for various conjugation ratios. Ho wever, ELISA with the A20 antibody fails to detect cap sids for the 50:1 and 100:1 ratios. A do t blot with t he A20 antibod y confirms th e lack of ca psid detect ion for the higher conjugation ratio (Fig. 6B) .
Taxol conjugation does not alter the binding of AAV to heparin, as reflected in the similar elution profile off of a heparin column (Fig.  7) . This property was leveraged to remo ve un -reacted taxol from the AAV-taxol conjugates (see below).
To remove un-reacted taxol from AAV-taxol conjugates, we proposed using extensive dialysis again st multiple buffer exchanges. Surprisingly, dialysis was not eff ective at re moving free taxol. Figure 8A shows the results of a control experiment where free t axol alone was dialyzed overnight. When assa yed on a dot blot, we see that t he anti-taxol antibody is able to detect the presence of taxol in the dialyzed solution. When added to cells, the unremoved free taxol killed cells (Fig. 8B.b) . To more effe ctively remove un-reacted taxol, we used h eparin affinity column to purify the AAV-taxol conjugat es. When t he column purified conjugates were added to cells, they exhi bited less acute cytotoxicity compared to the con jugates that were only dialyzed (Fig. 8B.c) . Live/dead assays are u nderway to determine the percenta ge of dead cells in each of these case s. A size exclusion column will also be tested to removed un-reacted taxol-NHS este r. Therefore, we have concluded t hat dialysis alone does not remove unreacted t axol and an alternative separation/purification strategy is required to isolate the AAV-ta xol conjugates. 
each clone. With a 50 M MnCl2 concentration, we are able to achieve 3 mutations per 1000 bp with no insertions or deletions that may potentially alter the reading frame. The estimated diversity of our EP-PCR library is 9.7x10 5 , which is very close to our d esired diversity of 10 6 . This EP-PCR library can then be used with staggered exte nsion proce ss (StEP) a s reported by Maheshri et al.( 1) to further increase the genetic diversity in the library. Detailed properties of one of our EP-PCR AAV cap plasmid libraries is listed in Table 2 .
Peptide display cap gene library. We have optimized peptide display methods to insert 7 r andom amino acid s in to the trop ism conferring domain of AAV2 cap as reported in Muller et al. (2) The seq uences of 10 randomly selected clones are listed in Tab le 3 and verify that the virus gene library is diverse. There is no apparent p attern in the identitie s o r types of amino acids that were in serted. An AAV peptide display library has been used previously by others to isolate virus variants t hat are able to transduce coronary artery cells which are normally resistant to AAV2 transduction. (2) Production of diverse AAV libraries. We have begun generating diverse AAV particle libraries based on the succe ssful plasmid libraries. T able 4 list s the diversity and virus titers of several of our recently generated libraries. Plasmid Libr ary EP 2 was generated with EP-PCR using 15 0 M Mn Cl 2 and AAV2 cap, and has an error ra te of around 6 mutations per 1000bp. Plasmid Library PD 1 B was generated using peptide display and contains a random seven amino acid insert in the AAV2 heparin binding do main. As a first pa ss to create virus particle libr aries with EP 2 and PD 1B plasmid libraries, 293T cells were transfecte d using a standard AAV transfection protocol using the librar y plasmid and pXX6 (encoding adenovirus helper functions). Due to viru s capsid self-assembly, this proto col could allow for chimeric capsid formation if a sin gle cell re ceived more than one member of the library. Virus titers for th ese libraries, 1.99E12 and 3.37E11 genomes/mL, were above our minimum threshold of 1E11 genomes/mL. Next, we produced virus particle librarie s EP 2 (S1) a nd EP 2 (S2 ) using a method to ensure that only one plasmid library member is delivered to each cell, gr eatly reducing the risk of chimeric cap sids (3) . In this method, a small amount of library plasmid is a dded and pBluescript is used as a 'stuffer' plasmid to facilitate the process. We are able to create very high titer virus libraries with this method (Table 4) . In summary, we have successf ully created hig h titer virus particle libraries usin g directed evolution. The librarie s are ready to be used in positive selection pr ocedures to isolate mutants able to transduce breast cell s with highe r efficiency. Future work will also include using virus librar ies of lower error rates, in case of EP-PCR, to minimize the potential of protein structure destabilizing mutations.
KEY RESEARCH ACCOMPLISHMENTS
• Synthesized taxol-2'-succinate, purified the product and confirmed the product by MALDI-MS.
• Synthesized taxol-NHS ester, purified the prod uct with column chromatography a nd confirmed by MALDI-MS.
• Conjugated taxol to AAV capsid surface through ester bonds. Conjugation was confirmed by Western blots using B1 and taxol antibodies. Table 4 . Diversity and titer of AAV libraries.
